An emerging biotech with transformative potential

About us

Anocca is a privately held Swedish biotechnology company founded in 2014 with the mission to establish a unique technology platform for analysis of T-cell biology to unlock the therapeutic potential of T-cell immunity.

Anocca’s technologies enable the highly precise and efficient analysis of T-cell biology required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas. With a focus on delivering TCR-modified T-cell therapies (TCR-T) in oncology, Anocca is rapidly progressing a pipeline of novel T-cell therapies towards clinical trials utilizing our own manufacturing capabilities.

Anocca’s powerful technologies are also being deployed to develop a range of novel therapeutic and prophylactic products in oncology, infectious disease and autoimmunity.

Company leadership

Anocca’s leadership represents diverse backgrounds and experience. Together, the Management team and Board of Directors, with collective experience from the pharmaceutical, engineering and finance sectors, along with deep scientific knowledge and business acumen, are taking the company to the next stage in its development.

Rolf Kiessling

Rolf Kiessling

Reagan Jarvis

Reagan Jarvis

Hans Stråberg

Hans Stråberg

Mike Nishimura

Mike Nishimura

Mikael Blomqvist

Mikael Blomqvist

Klas Kärre

Klas Kärre

Jacob Michlewicz

Jacob Michlewicz

Fredrik Hansson

Fredrik Hansson

Luke Pase

Luke Pase

Hugh Salter

Hugh Salter

Sophie Blomqvist

Sophie Blomqvist

Ryan Hill

Ryan Hill

Ragnar Lindqvist

Ragnar Lindqvist

Michael Kalos

Michael Kalos

Jan Lundberg

Jan Lundberg

Zahid Bashir

Zahid Bashir

Reagan Jarvis

Reagan Jarvis

Mark Farmery

Mark Farmery

Brian McGee

Brian McGee

Viktor Arnkil

Viktor Arnkil